Navigation Links
Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
Date:4/29/2009

STOCKHOLM, Sweden, April 29 /PRNewswire/ --

- Results to be Presented at World Congress of Nephrology 2009

Pharmalink AB announced today that it has completed its open Phase II trial evaluating the efficacy and safety of Nefecon(R) in IgA nephropathy, a glomerulonephritis leading to end-stage renal disease. Nefecon is an enteric formulation of a locally acting corticosteroid which downregulates the inflammatory process in the kidneys through suppression of the gut immune system.

Sixteen patients at trial centers in Sweden were treated for six months followed by a three month follow up period. Full results will be presented at the World Congress of Nephrology 2009, 22-26 May in Milan (Smerud et al, Enteric Budesonide Ameliorates Albuminuria and Glomerular Filtration Rate in IgA Nephropathy Patients) and at the satellite meeting, IgA Nephropathy, 26-28 May in Stresa, Italy.

"It is very gratifying to have completed this important stage in the development of Nefecon," said Johan Haggblad, Managing Director of Pharmalink. "We hope to bring a new licensed treatment where other therapies have failed and will now focus on preparing for pivotal trials and on seeking a development partner to bring Nefecon through Phase III and to the market."

Nefecon is being co-developed by Pharmalink and Archimedes Development Ltd ("Archimedes") a subsidiary of Archimedes Pharma Ltd under a partnership agreed in January 2004 to bring the product candidate to proof-of-concept. The concept underlying the renal disease product candidate Nefecon is a patented invention by Professors Bengt Fellstrom and Roger Hallgren at Uppsala University, Sweden. It is delivered using Archimedes' proprietary TARGIT(R) drug delivery technology which enables the localized delivery of drugs to the lower small intestine or colonic regions of the gut. Archimedes is providing access to the TARGIT platform and providing all trial supplies of Nefecon. Pharmalink is responsible for the management of the clinical trials.

About Pharmalink

Pharmalink AB is a privately held Swedish specialty pharma company that develops proprietary pharmaceutical products in fields of unmet medical need. Pharmalink has adopted a reformulation/repurposing strategy and has a vast international network of physicians, biotech companies, CMOs, CROs and specialist consultants. Pharmalink has a track record of introducing more than 15 pharmaceutical products to market. Pharmalink currently has three clinical phase development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablation prior to bone marrow transplantation. Pharmalink also seeks to refill its development pipeline by in-licensing.

About Archimedes Pharma

Archimedes Pharma ("Archimedes") is a pan-European specialty pharmaceutical company marketing and selling an expanding portfolio of specialist products to hospital-based prescribers in major European territories.

Archimedes is also developing a robust, high value pipeline of in-house products in pain, Parkinson's disease and critical care. It applies its world-class drug delivery technologies to proven molecules which have yet to achieve their market potential due to their current mode of delivery. This approach reduces the company's development risk, while delivering significant clinical and commercial benefits. The Group's lead development product is NasalFent(R), an innovative and highly differentiated fentanyl citrate nasal spray, for the rapid relief of breakthrough cancer pain.

Archimedes technologies - ChiSys(R), PecSys(TM) and TARGIT(R) - are used in a number of partnered products in late-stage clinical development.

TARGIT is Archimedes' proprietary technology for the delivery of drugs to specific regions of the large intestine or the local treatment of disease, an area of great interest to the pharmaceutical industry. The TARGIT system offers the option of delivering high local concentrations of drug, which are ideal for the topical treatment of diseases such as ulcerative colitis, Crohn's disease, irritable bowel syndrome and bacterial infections. The ability of TARGIT to reliably deliver drugs into the lower GIT has been demonstrated in numerous clinical studies.

    For more information, please visit:http://www.archimedespharma.com

    For further information, please contact:
    Pharmalink:
    Johan Haggblad, Managing Director, +46(0)70-668-0644
    Email: johan.haggblad@pharmalink.se
   http://www.pharmalink.se

    Archimedes Pharma:
    Michael Clark, +44-118-931-5077
   http://www.archimedespharma.com

    Citigate Dewe Rogerson (Pharmalink):
    Chris Gardner/Nina Enegren, +44-207-638-9571
    CapitalMSL (Archimedes):
    Mary Clark, Tel: +44-207-3075330



'/>"/>
SOURCE Pharmalink AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
3. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
6. Gen-Probe Completes Acquisition of Tepnel Life Sciences
7. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
8. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
9. Atritech Completes $30 Million Financing
10. Roche Completes Tender Offer for Genentech
11. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):